AstraZeneca's blockbuster Fasenra fails on one of two PhIII eosinophilic esophagitis trial endpoints
AstraZeneca has been looking to give itself an edge against other rival treatments in eosinophilic indications, such as GSK’s Nucala, but an initial readout from a Phase III trial may have now blunted that approach.
The pharma reported Tuesday morning that Fasenra, tested in a late-stage trial called MESSINA, did not meet one of the two dual-primary endpoints in eosinophilic esophagitis (EoE). EoE is a rare disease that occurs when eosinophils (a variety of white blood cells) accumulate in the esophagus, causing inflammation and leading to difficulty swallowing and pain.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.